AbClon Inc. (KOSDAQ:174900)
18,330
-140 (-0.76%)
Nov 2, 2026, 3:30 PM KST
AbClon Revenue
AbClon had revenue of 1.68B KRW in the quarter ending June 30, 2026, with 51.44% growth. This brings the company's total for the last twelve months to 5.31B, up 75.02% year-over-year. In the year 2025, AbClon had annual revenue of 4.71B with 101.47% growth. That makes AbClon the 40,700th largest company in the world by revenue and 2,513th in South Korea.
Revenue (ttm)
5.31B
Revenue Growth
+75.02%
P/S Ratio
69.43
Revenue / Employee
n/a
Employees
n/a
Market Cap
365.72B
Revenue by Geography
- South Korea 2.34B 99.8%
- Other 4.58M 0.2%
Fiscal year ended Dec 31, 2024 See the full AbClon breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.71B | 2.37B | 101.47% |
| Dec 31, 2024 | 2.34B | -537.21M | -18.67% |
| Dec 31, 2023 | 2.88B | -527.18M | -15.49% |
| Dec 31, 2022 | 3.40B | 386.15M | 12.79% |
| Dec 31, 2021 | 3.02B | 246.87M | 8.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| MEDIPOST | 74.84B |
| HLB Therapeutics | 64.45B |
| Pharmicell | 23.94B |
| SillaJen | 10.77B |
| GI Innovation | 5.50B |